Gibson Dunn Advised Arrowhead Pharmaceuticals on Asset Purchase Agreement with Sanofi
The global law firm Gibson Dunn is advising Arrowhead Pharmaceuticals on an asset purchase agreement between Sanofi and Visirna Therapeutics, a majority-owned subsidiary of Arrowhead. Under the agreement, Sanofi will acquire rights to develop and commercialize the investigational therapy plozasiran in Greater China.
The Gibson Dunn corporate team is led by partner Karen Alexandra Spindler (San Francisco) and includes partner Jin Hee Kim (New York) and associates Paul Rafla (New York) and Sonari Chidi (Los Angeles). Partners Pamela Lawrence Endreny (New York) and Benjamin Rapp (Munich, Frankfurt) and associate Ryan Rott (New York) advised on tax matters. Partner Cassandra Gaedt-Sheckter (Palo Alto) and associate Courtney Wang (San Francisco) advised on data privacy, while partner John Partridge (Denver) and of counsel Ning Ning (Hong Kong) provided guidance on compliance.
Click to know more about Gibson Dunn
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at [email protected] or call us on +91 8879634922.